134 related articles for article (PubMed ID: 25319874)
21. RET codon 609 mutations: a contribution for better clinical managing.
Mian C; Sartorato P; Barollo S; Zane M; Opocher G
Clinics (Sao Paulo); 2012; 67 Suppl 1(Suppl 1):33-6. PubMed ID: 22584703
[TBL] [Abstract][Full Text] [Related]
22. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.
Marsh DJ; Mulligan LM; Eng C
Horm Res; 1997; 47(4-6):168-78. PubMed ID: 9167949
[TBL] [Abstract][Full Text] [Related]
23. Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations.
Learoyd DL; Gosnell J; Elston MS; Saurine TJ; Richardson AL; Delbridge LW; Aglen JV; Robinson BG
Clin Endocrinol (Oxf); 2005 Dec; 63(6):636-41. PubMed ID: 16343097
[TBL] [Abstract][Full Text] [Related]
24. [Familial medullary thyroid carcinoma: case report and literature review.].
Barletta Carrillo CF; Poterico Rojas JA; Barrionuevo Cornejo C; Casavilca Zambrano S; Pinedo Cárdenas A; Quispe Santibañez I; Castro Mujica MDC
Rev Fac Cien Med Univ Nac Cordoba; 2018 Dec; 75(4):303-309. PubMed ID: 30734711
[TBL] [Abstract][Full Text] [Related]
25. RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma.
Krampitz GW; Norton JA
Cancer; 2014 Jul; 120(13):1920-31. PubMed ID: 24699901
[TBL] [Abstract][Full Text] [Related]
26. A Nationwide Study of Multiple Endocrine Neoplasia Type 2A in Norway: Predictive and Prognostic Factors for the Clinical Course of Medullary Thyroid Carcinoma.
Opsahl EM; Brauckhoff M; Schlichting E; Helset K; Svartberg J; Brauckhoff K; Mæhle L; Engebretsen LF; Sigstad E; Grøholt KK; Akslen LA; Jørgensen LH; Varhaug JE; Bjøro T
Thyroid; 2016 Sep; 26(9):1225-38. PubMed ID: 27400880
[TBL] [Abstract][Full Text] [Related]
27. Various penetrance of familial medullary thyroid carcinoma in patients with RET protooncogene codon 790/791 germline mutations.
Fitze G; Schierz M; Bredow J; Saeger HD; Roesner D; Schackert HK
Ann Surg; 2002 Nov; 236(5):570-5. PubMed ID: 12409662
[TBL] [Abstract][Full Text] [Related]
28. Change in the spectrum of RET mutations diagnosed between 1994 and 2006.
Frank-Raue K; Rondot S; Schulze E; Raue F
Clin Lab; 2007; 53(5-6):273-82. PubMed ID: 17605401
[TBL] [Abstract][Full Text] [Related]
29. A novel germline variant in RET gene resulting in an additional cysteine in a family with familial medullary thyroid carcinoma.
Oriola J; Sanchez A; Paniello B; de la Bellacasa JP; Biarnés J
Fam Cancer; 2021 Jul; 20(3):253-256. PubMed ID: 33084974
[TBL] [Abstract][Full Text] [Related]
30. New presentation of familial medullary thyroid carcinoma in 87-year-old patient with high-risk RET proto-oncogene codon 620 mutation.
Jaggard MK; MacRae C; Ifeacho S; Robinson S; Tolley NS
J Laryngol Otol; 2009 Jul; 123(7):796-800. PubMed ID: 18771606
[TBL] [Abstract][Full Text] [Related]
31. RET mutation p.S891A in a Chinese family with familial medullary thyroid carcinoma and associated cutaneous amyloidosis binding OSMR variant p.G513D.
Qi XP; Zhao JQ; Chen ZG; Cao JL; Du J; Liu NF; Li F; Sheng M; Fu E; Guo J; Jia H; Zhang YM; Ma JM
Oncotarget; 2015 Oct; 6(32):33993-4003. PubMed ID: 26356818
[TBL] [Abstract][Full Text] [Related]
32. Multiple endocrine neoplasia type 2A with the identical somatic mutation in medullary thyroid carcinoma and pheochromocytoma without germline mutation at the corresponding site in the RET proto-oncogene.
Akama H; Noshiro T; Kimura N; Shimizu K; Watanabe T; Shibukawa S; Nakai S; Miura W; Ito S; Miura Y
Intern Med; 1999 Feb; 38(2):145-9. PubMed ID: 10225670
[TBL] [Abstract][Full Text] [Related]
33. Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2.
Moore SW; Appfelstaedt J; Zaahl MG
J Pediatr Surg; 2007 Feb; 42(2):326-32. PubMed ID: 17270543
[TBL] [Abstract][Full Text] [Related]
34. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
Komminoth P; Kunz EK; Matias-Guiu X; Hiort O; Christiansen G; Colomer A; Roth J; Heitz PU
Cancer; 1995 Aug; 76(3):479-89. PubMed ID: 8625130
[TBL] [Abstract][Full Text] [Related]
35. All in the family? Analyzing the impact of family history in addition to genotype on medullary thyroid carcinoma aggressiveness in MEN2A patients.
Long KL; Etzel C; Rich T; Hyde S; Perrier ND; Graham PH; Lee JE; Hu MI; Cote GJ; Gagel R; Grubbs EG
Fam Cancer; 2017 Apr; 16(2):283-289. PubMed ID: 27864651
[TBL] [Abstract][Full Text] [Related]
36. Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma.
D'Aloiso L; Carlomagno F; Bisceglia M; Anaganti S; Ferretti E; Verrienti A; Arturi F; Scarpelli D; Russo D; Santoro M; Filetti S
J Clin Endocrinol Metab; 2006 Mar; 91(3):754-9. PubMed ID: 16384843
[TBL] [Abstract][Full Text] [Related]
37. Modifying impact of
Kaczmarek-Ryś M; Ziemnicka K; Pławski A; Budny B; Michalak M; Hryhorowicz S; Hoppe-Gołębiewska J; Boruń P; Gołąb M; Czetwertyńska M; Sromek M; Szalata M; Ruchała M; Słomski R
Endocr Relat Cancer; 2018 Apr; 25(4):421-436. PubMed ID: 29386230
[TBL] [Abstract][Full Text] [Related]
38. Chinese siblings with hereditary medullary thyroid carcinoma caused by RET mutation: implications for RET oncogene detection.
Huang Q; Hu A; Zhang M
BMC Endocr Disord; 2020 May; 20(1):64. PubMed ID: 32408902
[TBL] [Abstract][Full Text] [Related]
39. Unusual presentation of multiple endocrine neoplasia type 2A in a patient with the C634R mutation of the RET-protooncogene.
Harzallah F; Barlier A; Feki M; Enjalbert A; Slimane H
Ann Endocrinol (Paris); 2008 Dec; 69(6):523-5. PubMed ID: 18752792
[TBL] [Abstract][Full Text] [Related]
40. The rare intracellular RET mutation p.S891A in a Chinese Han family with familial medullary thyroid carcinoma.
Qi XP; Zhang RX; Cao JL; Chen ZG; Jin HY; Yang RR
J Biosci; 2014 Jun; 39(3):505-12. PubMed ID: 24845513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
